Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea

Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea

A huge congratulations to BioLife customer TissueGene / Kolon Life Science on their first patient use of CryoStor – powered Invossa, a novel cell-mediated therapy for degenerative arthritis. Invossa is the world’s first gene therapy for treating osteoarthritis of the knee, in which the cartilage that cushions the joints wears away, causing the bones to rub together and induce pain. A single injection of the drug delivers therapeutic relief for up to two years, according to the firm. It was developed by Kolon Group’s US-based bioparma subsidiary TissueGene, which went public on the Kosdaq recently. To read more, visit this article.